| June 17, 2026 | Utebzi (tebipenem pivoxil hydrobromide) | GSK | FDA approval | — | Approved | FDA Novel Drug Approvals |
| June 17, 2026 | GSK3036656 | GSK | Topline readout | Tuberculosis | Completed | ClinicalTrials.gov |
| Jun 2026Month disclosed | — | GSK | FDA approval | complicated urinary tract infections | Approved | SEC Form 8-K |
| May 27, 2026 | Vocabria (cabotegravir sodium) | GSK | Primary completion | HIV Infections | Completed | ClinicalTrials.gov |
| May 18, 2026 | Nucala (mepolizumab) | GSK | Topline readout | Asthma | Completed | ClinicalTrials.gov |
| May 14, 2026 | GSK4527226 | GSK | Primary completion | Alzheimer's Disease | Withdrawn | ClinicalTrials.gov |
| May 14, 2026 | dtg/3tc | GSK | Topline readout | HIV; HIV Infections | Completed | ClinicalTrials.gov |
| May 11, 2026 | flu mrna (formulation a) (GSK6479720A) | GSK | Primary completion | Influenza, Human | Completed | ClinicalTrials.gov |
| May 4, 2026 | Nucala (mepolizumab) | GSK | Topline readout | Hypereosinophilic Syndrome | Completed | ClinicalTrials.gov |
| April 15, 2026 | Tivicay (dolutegravir sodium) | GSK | Primary completion | HIV; HIV Infections | Completed | ClinicalTrials.gov |
| March 24, 2026 | linerixibat (GSK2330672) | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| March 9, 2026 | Wellcovorin (leucovorin calcium) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| Mar 2026Month disclosed | — | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| January 31, 2026 | GSK4532990 | GSK | Primary completion | Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease | Completed | ClinicalTrials.gov |
| January 23, 2026 | dtg/3tc | GSK | Primary completion | HIV; HIV Infections | Completed | ClinicalTrials.gov |
| January 15, 2026 | gsk3511294 (depemokimab) (GSK3511294) | GSK | Topline readout | Asthma | Completed | ClinicalTrials.gov |
| January 14, 2026 | zanamivir | GSK | Primary completion | Influenza, Human; Arthralgia | Completed | ClinicalTrials.gov |
| December 16, 2025 | Exdensur (depemokimab-ulaa) | GSK | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| December 16, 2025 | Exdensur (depemokimab-ulaa) | GSK | FDA approval | — | Approved | FDA Novel Drug Approvals |
| December 15, 2025 | rmenb+omv nz vaccine | GSK | Primary completion | Meningitis | Completed | ClinicalTrials.gov |
| December 11, 2025 | Blujepa (gepotidacin mesylate) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 11, 2025 | — | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| Dec 2025Month disclosed | azithromycin | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| Dec 2025Month disclosed | — | GSK | Label expansion | uncomplicated urogenital gonorrhoea in patients 12 years of age and older | Approved | SEC Form 8-K |
| November 11, 2025 | HIBSAGO (bepirovirsen) | GSK | Primary completion | Chronic Hepatitis B; Hepatitis B, Chronic | Completed | ClinicalTrials.gov |
| November 3, 2025 | HIBSAGO (bepirovirsen) | GSK | Primary completion | Chronic Hepatitis B; Hepatitis B, Chronic | Completed | ClinicalTrials.gov |
| October 28, 2025 | Nucala (mepolizumab) | GSK | Primary completion | Hypereosinophilic Syndrome | Completed | ClinicalTrials.gov |
| October 27, 2025 | efimosfermin (BOS-580) | GSK | Primary completion | Nonalcoholic Steatohepatitis (NASH) | Completed | ClinicalTrials.gov |
| October 23, 2025 | Blenrep (belantamab mafodotin-blmf) | GSK | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| October 23, 2025 | Blenrep (belantamab mafodotin-blmf) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |
| October 23, 2025 | — | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| October 21, 2025 | altsonflex1-2-3 dose a | GSK | Primary completion | Diarrhoea | Completed | ClinicalTrials.gov |
| October 1, 2025 | GSK3915393 | GSK | Primary completion | Idiopathic Pulmonary Fibrosis | Withdrawn | ClinicalTrials.gov |
| September 23, 2025 | GSK4532990 | GSK | Primary completion | Non-alcoholic Fatty Liver Disease | Completed | ClinicalTrials.gov |
| September 18, 2025 | AFX3772 | GSK | Primary completion | Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal | Completed | ClinicalTrials.gov |
| September 16, 2025 | dtg/3tc | GSK | Primary completion | HIV Infections | Completed | ClinicalTrials.gov |
| September 14, 2025 | Nucala (mepolizumab) | GSK | Primary completion | Asthma | Completed | ClinicalTrials.gov |
| September 2, 2025 | salbutamol hfa-134a | GSK | Primary completion | Asthma | Completed | ClinicalTrials.gov |
| August 5, 2025 | HIBSAGO (bepirovirsen) | GSK | Primary completion | Hepatitis B, Chronic | Completed | ClinicalTrials.gov |
| July 30, 2025 | — | GSK | Advisory committee | — | Completed | SEC Form 8-K |
| July 29, 2025 | GSK1070806 | GSK | Primary completion | Dermatitis, Atopic | Withdrawn | ClinicalTrials.gov |
| July 23, 2025 | GSK1070806 | GSK | Primary completion | Dermatitis, Atopic | Withdrawn | ClinicalTrials.gov |
| July 23, 2025 | — | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| July 17, 2025 | Blenrep (belantamab mafodotin-blmf) | GSK | Advisory committee | — | Negative | FDA advisory committee calendar |
| June 20, 2025 | Benlysta (belimumab) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 18, 2025 | ZEJULA (niraparib) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 5, 2025 | cobolimab (GSK4069889) | GSK | Primary completion | Lung Cancer, Non-Small Cell | Completed | ClinicalTrials.gov |
| June 3, 2025 | rsvpref3 oa investigational vaccine | GSK | Primary completion | Respiratory Syncytial Virus Infections | Completed | ClinicalTrials.gov |
| May 27, 2025 | GSK3036656 | GSK | Primary completion | Tuberculosis | Completed | ClinicalTrials.gov |
| May 22, 2025 | Nucala (mepolizumab) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 19, 2025 | gsk3511294 (depemokimab) (GSK3511294) | GSK | Primary completion | Asthma | Completed | ClinicalTrials.gov |
| March 25, 2025 | Blujepa (gepotidacin mesylate) | GSK | FDA approval | To treat uncomplicated urinary tract infections | Approved | FDA Novel Drug Approvals |
| Mar 2025Month disclosed | — | GSK | FDA approval | female adults | Approved | SEC Form 8-K |
| February 14, 2025 | — | GSK | FDA approval | — | Approved | SEC Form 8-K |
| February 14, 2025 | — | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| September 20, 2024 | Cabenuva Kit (cabotegravir; rilpivirine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 20, 2024 | Vocabria (cabotegravir sodium) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 1, 2024 | Jemperli (dostarlimab-gxly) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 16, 2024 | Benlysta (belimumab) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 5, 2024 | Dovato (dolutegravir sodium; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 15, 2023 | OJJAARA (momelotinib) | GSK | FDA approval | To treat intermediate or high-risk myelofibrosis in adults with anemia | Approved | FDA Novel Drug Approvals |
| Sep 2023Month disclosed | — | GSK | PDUFA date | — | Scheduled | SEC Form 8-K |
| July 31, 2023 | Jemperli (dostarlimab-gxly) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 15, 2023 | Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 26, 2023 | ZEJULA (niraparib) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 26, 2023 | ZEJULA (niraparib) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 1, 2023 | Arnuity Ellipta (fluticasone furoate) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 15, 2023 | Benlysta (belimumab) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 9, 2023 | Jemperli (dostarlimab-gxly) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 1, 2023 | Jesduvroq (daprodustat) | GSK | FDA approval | — | Approved | FDA Novel Drug Approvals |
| January 25, 2023 | Dovato (dolutegravir sodium; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 8, 2022 | ZEJULA (niraparib) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 30, 2022 | Brexafemme (ibrexafungerp) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 30, 2022 | Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 30, 2022 | Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 23, 2022 | Cabenuva Kit (cabotegravir; rilpivirine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 23, 2022 | Vocabria (cabotegravir sodium) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 31, 2022 | Cabenuva Kit (cabotegravir; rilpivirine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 31, 2022 | Vocabria (cabotegravir sodium) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 24, 2022 | Rukobia (fostemsavir tromethamine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 20, 2022 | Dovato (dolutegravir sodium; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 20, 2021 | Vocabria (cabotegravir sodium) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 20, 2021 | Vocabria (cabotegravir sodium) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 10, 2021 | Epzicom (abacavir sulfate; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 17, 2021 | Jemperli (dostarlimab-gxly) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |
| July 29, 2021 | Nucala (mepolizumab) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 9, 2021 | Juluca (dolutegravir sodium; rilpivirine hydrochloride) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 9, 2021 | Tivicay (dolutegravir sodium) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 1, 2021 | Brexafemme (ibrexafungerp) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |